Rare cancers—Rarity as a cost and value argument
Authors:
- J.-Matthias Graf von der SchulenburgJSJ.-Matthias Graf von der Schulenburg
- Frédéric PauerFPFrédéric Pauer
- 1 March 2017
- journal article
- Published by Elsevier in Journal of Cancer Policy
- Vol. 11, 54-59
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers InitiativeEuropean Journal of Cancer, 2015
- Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher diseaseOrphanet Journal of Rare Diseases, 2014
- Estimating the budget impact of orphan drugs in Sweden and France 2013–2020Orphanet Journal of Rare Diseases, 2014
- Rare cancers are not so rare: The rare cancer burden in EuropeEuropean Journal of Cancer, 2011
- The Burden of Rare Cancers in Europe2010
- The Occurrence of Rare Cancers in U.S. Adults, 1995–2004Public Health Reports®, 2010
- Are We Finally Winning the War on Cancer?Journal of Economic Perspectives, 2008
- Assessing the economic challenges posed by orphan drugsInternational Journal of Technology Assessment in Health Care, 2007
- Orphan drugs and the NHS: should we value rarity?BMJ, 2005
- The Voluntary Exchange Theory of Public EconomyThe Quarterly Journal of Economics, 1939